

Clinical trials of poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in all type of patient (BRCA mutated or not)

TrialResults-center www.trialresultscenter.org

1 PARP inhibitors

Trial	Treatments	Patients	Trials design and methods
rucaparib vs chemotherapy			
ARIEL 4 <i>ongoing</i> [NCT02855944] n=NA follow-up:	Oral rucaparib 600 mg BID versus Chemotherapy will be administered per local standard of care and regulations	Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Parallel groups open
niraparib vs placebo			
ENGOT-OV16/NOVA gBRCA , 2017 [NCT01847274] n=138/65 follow-up:	niraparib (300 mg) once daily as maintenance treatment versus placebo	patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation	Parallel groups double-blind
ENGOT-OV16/NOVA non-gBRCA [NCT01847274] n=138/65 follow-up:	niraparib (300 mg) once daily versus placebo	patients with platinum-sensitive, recurrent ovarian cancer	Parallel groups double-blind
olaparib vs placebo			
SOLO2/ENGOT-Ov21 [NCT01874353] n=196/99 follow-up:	olaparib 300 mg in two 150 mg tablets, twice daily versus placebo	patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation	double-blind international
olaparid vs placebo			
Ledermann , 2012 [NCT00753545] n=136/129 follow-up:	olaparib, at a dose of 400 mg twice daily versus placebo	patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations, who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen	double-blind
rucaparib vs placebo			
ARIEL 3 <i>ongoing</i> [NCT01968213] n=NA follow-up:	maintenance treatment with rucaparib versus placebo	maintenance treatment	Parallel groups double-blind

References

ARIEL 4, :

ENGOT-OV16/NOVA gBRCA, 2017:

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Drum A, Tinker AV, du Bois A, Gonzalez-Martn A, Follana P, Benigno B, Rosenberg P, Gilb Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med* 2016;375:2154-2164 [[27717299](#)]

ENGOT-OV16/NOVA non-gBRCA, :

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Drum A, Tinker AV, du Bois A, Gonzalez-Martn A, Follana P, Benigno B, Rosenberg P, Gilb Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med* 2016;375:2154-2164 [[27717299](#)]

SOLO2/ENGOT-Ov21, :

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017;: [[28754483](#)]

Ledermann, 2012:

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382-92 [[22452356](#)]

ARIEL 3, :

2

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.